Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2024 08:30 ET | Source: Surrozen, Inc.

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary FIbrosis
March 03, 2022 08:01 ET | Source: Oncotelic Therapeutics, Inc.

Dr. Anthony E. Maida will be presenting at the Marcus Evans Evolution Summit

AGOURA HILLS, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), and Marcus Evans are proud to announce Dr Anthony E. Maida, Chief...
February 24, 2022 08:47 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Presenting at MedInvest Pharmaceutical and Biotechnology Investor Conference

OT-101 is Oncotelic’s RNA Therapeutic Against TGF-βOT-101 has completed over six clinical trials against solid tumors with good efficacyOT-101 is currently undergoing a phase 1b trial in combination...
February 24, 2022 08:01 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Presenting at BiotechGate Digital Partnering

OT-101 is Oncotelic’s RNA Therapeutic Against TGF-βOT-101 has completed over six clinical trials against solid tumors with good efficacyOT-101 is currently undergoing a phase 1b trial in combination...
January 19, 2022 09:05 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Presenting at BiotechGate Digital Partnering

OT-101 is Oncotelic’s RNA Therapeutic Against TGF-βOT-101 has completed over six clinical trials against solid tumors with good efficacyOT-101 is currently undergoing a phase 1b trial in combination...
March 08, 2021 07:00 ET | Source: Mateon Therapeutics, Inc.

MATEON’S UPDATE ON C001 - GLOBAL STUDY FOR OT-101 AGAINST COVID-19

PART 1 AND 2 SENTINEL PATIENTS COMPLETED TREATMENT THE FIRST COHORT OF 18 PART 1 PATIENTS COMPLETED TREATMENT. AGOURA HILLS, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics,...